131 related articles for article (PubMed ID: 31022347)
1. Compensated Interferometry Measures of CYFRA 21-1 Improve Diagnosis of Lung Cancer.
Kammer MN; Kussrow AK; Webster RL; Chen H; Hoeksema M; Christenson R; Massion PP; Bornhop DJ
ACS Comb Sci; 2019 Jun; 21(6):465-472. PubMed ID: 31022347
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in the lung cancer diagnosis: a clinical perspective.
Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
[TBL] [Abstract][Full Text] [Related]
3. Development of a Protein Biomarker Panel to Detect Non-Small-Cell Lung Cancer in Korea.
Jung YJ; Katilius E; Ostroff RM; Kim Y; Seok M; Lee S; Jang S; Kim WS; Choi CM
Clin Lung Cancer; 2017 Mar; 18(2):e99-e107. PubMed ID: 27836219
[TBL] [Abstract][Full Text] [Related]
4. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
5. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
6. Assay Performance of a Label-Free, Solution-Phase CYFRA 21-1 Determination.
Kussrow AK; Kammer MN; Massion PP; Webster R; Bornhop DJ
ACS Omega; 2022 Sep; 7(36):31916-31923. PubMed ID: 36120008
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
8. Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry.
Olmsted IR; Hassanein M; Kussrow A; Hoeksema M; Li M; Massion PP; Bornhop DJ
Anal Chem; 2014 Aug; 86(15):7566-74. PubMed ID: 24954171
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
10. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
11. Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung.
Muley T; He Y; Rolny V; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Meister M; Herth FJ; Dayyani F
Lung Cancer; 2019 Apr; 130():194-200. PubMed ID: 30885344
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.
Niklinski J; Furman M; Chyczewska E; Chyczewski L; Rogowski F; Laudanski J
Eur Respir J; 1995 Feb; 8(2):291-4. PubMed ID: 7538933
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of Cyfra 21-1 estimation for lung cancer patients.
Szturmowicz M; Sakowicz A; Rudzinski P; Zych J; Wiatr E; Zaleska J; Rowinska-Zakrzewska E
Int J Biol Markers; 1996; 11(3):172-7. PubMed ID: 8915713
[TBL] [Abstract][Full Text] [Related]
14. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
15. Cross-Sectional Study to Establish the Utility of Serum Tumor Markers in the Diagnosis of Lung Cancer.
Mehta A; Parkash A; Bhatia M
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2569-2576. PubMed ID: 34452572
[TBL] [Abstract][Full Text] [Related]
16. Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
Wojcik E; Tarapacz J; Rychlik U; Stasik Z; Sas-Korczynska B; Skotnicki P; Kulpa JK
Clin Lab; 2016 Sep; 62(9):1625-1632. PubMed ID: 28164590
[TBL] [Abstract][Full Text] [Related]
17. Preoperative serum CYFRA 21-1 level as a prognostic factor in surgically treated adenocarcinoma of lung.
Park SY; Lee JG; Kim J; Park Y; Lee SK; Bae MK; Lee CY; Kim DJ; Chung KY
Lung Cancer; 2013 Feb; 79(2):156-60. PubMed ID: 23206831
[TBL] [Abstract][Full Text] [Related]
18. Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer.
Pavićević R; Milicić J; Bubanović G; Supe S
Coll Antropol; 1998 Dec; 22(2):629-35. PubMed ID: 9887620
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance and prognostic value of pentraxin-3 as serologic biomarker for lung cancer.
Zhang D; Ren WH; Gao Y; Wang NY; Wu WJ
Asian Pac J Cancer Prev; 2013; 14(7):4215-21. PubMed ID: 23991979
[TBL] [Abstract][Full Text] [Related]
20. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]